Table 4.

Demographics

	Sorafenib alone in prostate cancer	Sorafenib alone in lung cancer	Combination sorafenib and bevacizumab
Age
Range (Median)	48–88 (66)	35–84 (64)	30–76 (58)
Sex
Male	41	8	14
Female	0	5	28
Patients treated with prior
Taxanes
Liposomal doxorubicin	31	11	26
	0	0	12
Number of prior treatments	1–8(4)	1–7(1)	1–15(6)
Tumor type	Prostate 41	NSCLC 13	EOC 15 Melanoma 7 Sarcoma 5 Breast 3 Renal 3 Colorectal 2 Others* 7
Cycles administered†
Range (median)	1 – 10 (2)	1 – 7 (3)	1 – 26+ (median 4)
Cumulative sorafenib dose in mg††
Range (median)	4,800 – 200,000 (44,000)	16,800 – 95,600 (44,800)	4600 – 174,200 (32,900)

NSCLC = Non-small cell lung cancer EOC = Epithelial ovarian cancer

^*Uterine adenocarcinoma (1), endometrial carcinoma (1), thyroid (1), testicular (1), adrenal (1), basal cell carcinoma (1), and cervix (1)

^†p=0.0002

^††p = 0.19